EU fines generic-drug companies to end "pay for delay" deals

06/3/2013 | Chicago Tribune (tiered subscription model)

The European Commission has announced fines against Lundbeck in Denmark, Merck in Germany and seven smaller firms for arrangements under which brand-name drug companies paid generic manufacturers to delay production of cheaper off-patent medicines. The fines mark a continuing effort by EU and US regulators to end such "pay for delay" tactics by large pharmaceutical firms. Lundbeck denied wrongdoing.

View Full Article in:

Chicago Tribune (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN